DeepMed Research

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: LBH589
Drug: Capecitabine
Drug: Lapatinib

First Posted Date: 2008-03-10

Last Posted Date: 2015-06-08

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 20

Registration Number: NCT00632489

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: nab paclitaxel
Drug: Cyclophosphamide
Drug: Trastuzumab

First Posted Date: 2008-03-06

Last Posted Date: 2021-11-24

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 63

Registration Number: NCT00629499

Locations: 🇺🇸
Gulfcoast Oncology Associates, Saint Petersburg, Florida, United States
🇺🇸
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States

and more 7 locations

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel/Carboplatin
Drug: Docetaxel/Carboplatin/Bevacizumab/Erlotinib

First Posted Date: 2008-02-22

Last Posted Date: 2015-06-08

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 112

Registration Number: NCT00621049

Locations: 🇺🇸
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 23 locations

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Phase 1

Completed

Conditions: Refractory Malignancy

Interventions: Drug: Capecitabine and Sorafenib

First Posted Date: 2008-02-12

Last Posted Date: 2013-02-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 32

Registration Number: NCT00613145

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

Phase 1

Completed

Conditions: Refractory Malignancy
Solid Tumors

Interventions: Drug: Imatinib and PTK/ZK222584

First Posted Date: 2008-02-11

Last Posted Date: 2013-02-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 45

Registration Number: NCT00611689

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Phase 1

Completed

Conditions: Refractory Malignancy
Advanced Malignancies

Interventions: Drug: PTK787/ZK222584 and Bevacizumab

First Posted Date: 2008-02-11

Last Posted Date: 2009-01-23

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00611793

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Sorafenib
Drug: Erlotinib

First Posted Date: 2008-02-07

Last Posted Date: 2016-04-08

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 53

Registration Number: NCT00609804

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States

and more 13 locations

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib + Sorafenib
Drug: Erlotinib + Placebo

First Posted Date: 2008-01-24

Last Posted Date: 2022-03-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 166

Registration Number: NCT00600015

Locations: 🇺🇸
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus, Ohio, United States

and more 13 locations

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Panobinostat

First Posted Date: 2008-01-15

Last Posted Date: 2021-11-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 26

Registration Number: NCT00594230

Locations: 🇺🇸
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 4 locations

RAD001 Plus Bevacizumab in Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Bevacizumab
Drug: Everolimus

First Posted Date: 2008-01-11

Last Posted Date: 2021-11-24

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 57

Registration Number: NCT00591734

Locations: 🇺🇸
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy